Oncology treatment developer Relay Therapeutics is advancing research from several universities and has now filed for a $200m IPO.

Relay Therapeutics, a US-based oncology therapy developer based on research from multiple institutions, filed on Wednesday to raise up to $200m in an initial public offering. Relay is developing targeted small molecule cancer drugs using discoveries in protein motion and how it relates to the function of proteins that had previously been regarded as undruggable.…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.